VIDEO: Ubrogepant may prevent headache when dosed in prodromal phase
Click Here to Manage Email Alerts
BOSTON — Fewer patients who took ubrogepant during the premonitory phase went on to have headache when compared with placebo, Peter Goadsby, MD, PhD, FRS, said in this Healio video at the American Academy of Neurology annual meeting.
The PRODROME study is a randomized, double-blind, placebo-controlled crossover study that evaluated treating adults during the premonitory, or prodromal, phase of migraine, Goadsby, director of the NIHR Clinical Research Facility and professor of neurology at Kings College London and University of California, Los Angeles, said.
According to Goadsby, prodromal symptoms, such as photophobia and cognitive dysfunction, were reduced by ubrogepant 100 mg, and fewer patients went on to have headache at 24 hours.
“There’s no reason for people to have pain if they don’t have to have it, and the study shows you can stop the attack before it comes,” Goadsby said. “Seventy-five percent had some form of functional disability during the premonitory phase, and that could be reversed by the treatment.”